{
    "pmcid": "10590698",
    "qa_pairs": {
        "In which animal model did the nanobodies show significant protection against lethal viral challenges?": [
            "Severe COVID-19 mouse model",
            "Mild COVID-19 hamster model",
            "Severe COVID-19 rat model",
            "Mild COVID-19 guinea pig model"
        ],
        "What potential future application for nanobodies is suggested in the study?": [
            "Formulating nanobodies for aerosol inhalation",
            "Developing nanobodies for oral administration",
            "Using nanobodies in topical creams",
            "Injecting nanobodies directly into the bloodstream"
        ],
        "What was the method used to enhance the stability and half-life of the selected nanobodies?": [
            "Fusing them with the Fc domain of human IgG",
            "Conjugating them with polyethylene glycol",
            "Encapsulating them in liposomes",
            "Attaching them to gold nanoparticles"
        ],
        "What was the primary source of the nanobodies used in the study?": [
            "Alpacas",
            "Llamas",
            "Camels",
            "Mice"
        ],
        "Which nanobody demonstrated the broadest neutralization coverage against SARS-CoV-2 variants?": [
            "aVHH-13-Fc",
            "aVHH-11-Fc",
            "aVHH-14-Fc",
            "aVHH-12-Fc"
        ]
    }
}